首页> 外文OA文献 >Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence

【2h】

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence

机译：肿瘤突变作为预测生物标志物，用于反应免疫检查点抑制剂：对当前证据进行审查

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Samuel J. Klempner; David Fabrizio; Shalmali Bane; Marcia Reinhart; Tim Peoples; Siraj M. Ali; Ethan S. Sokol; Garrett Frampton; Alexa B. Schrock; Rachel Anhorn; Prasanth Reddy;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence [J] . Zeitschrift fur Arznei- und Gewurzpflanzen . 2020,第1期

机译：肿瘤突变负担作为一种预测生物标志物，用于反应免疫检查点抑制剂：对当前证据的审查
2. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence [J] . Klempner Samuel J., Fabrizio David, Bane Shalmali, The oncologist . 2020,第1期

机译：肿瘤突变负担作为一种预测生物标志物，用于反应免疫检查点抑制剂：对当前证据的审查
3. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence [J] . Samuel J. Klempner, Rachel Anhorn, Prasanth Reddy, The oncologist . 2020,第1期

机译：肿瘤突变负担作为一种预测生物标志物，用于反应免疫检查点抑制剂：对当前证据的审查
4. Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma [C] . Yeul Hong Kim, Hye Sook Kim, Jae Sook Sung, Molecular Medicine TRI-CON. . 2014

机译：下一代测序对非小细胞肺癌抗蛋白酶激酶抑制剂进行下一代测序检测的低负荷EGFR突变的预测疗效
5. Understanding How Adrenergic Stress Signaling Impacts the Anti-Tumor Immune Response and the Efficacy of Checkpoint Inhibitors in Murine Tumor Models [D] . Bucsek, Mark Joseph. 2019

机译：了解肾上腺素能应激信号如何影响抗肿瘤免疫应答以及检查点抑制剂在鼠肿瘤模型中的疗效
6. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence [O] . Samuel J. Klempner, David Fabrizio, Shalmali Bane, 2020

机译：肿瘤突变负担作为对免疫检查点抑制剂反应的预测性生物标志物：当前证据的回顾。
7. Combined Model of Frameshift Mutations and Tumor Mutation Burden in Predicting Preliminary Response to Immune Checkpoint Inhibitors in NSCLC [O] . Huaqiang Zhou, Jiaqing Liu, Yaxiong Zhang, 2019

机译：框架突变与肿瘤突变负担的组合模型预测NSCLC中免疫检查点抑制剂的初步反应

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence

著录项

引文网络

相似文献

相关主题

期刊订阅